BASELINE FRAILTY EVALUATION IN DRUG DEVELOPMENT

Using of frailty model baseline proportional hazard rate in Real Data Analysis

Many populations encountered in survival analysis are often not homogeneous. Individuals are flexible in their susceptibility to causes of death, response to treatment and influence of various risk factors. Ignoring this heterogeneity can result in misleading conclusions. To deal with these problems, the proportional hazard frailty model was introduced. In this paper, the frailty model is ex...

Points to consider on frailty: Evaluation instruments for baseline characterisation of clinical trial populations

Points to consider on frailty: Evaluation instruments for baseline characterisation of clinical trial populations

Evaluation and Management of Frailty

This chapter underscores the importance of interprofessional collaboration in the care of frail older patients. Hospital-based care is emphasized because interprofessionalism is difficult in that setting since the setting is constantly changing and since multiple healthcare professionals care for many complex, very ill patients, only some of whom are frail older people. Interprofessionalism is ...

Evaluation of Drug Abuse Relapse Event Rate Over Time in Frailty Model

OBJECTIVES Drug dependence as a chronic disorder is reversible over time and has a cost burden for individuals, families, and society. An individual who has stopped taking drugs for a long time may start taking drugs again. The variables affecting the reuse of drugs are not well known. Therefore a study of the factors that increase the length of time away from drugs is essential. METHODS This...